

# Neurotech

21 September 2021

## IRD Invest Conference: Webinar Presentation

**Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company")** is pleased to announce that Company Chairman, Brian Leedman will be presenting at the IRD Invest virtual investor conference, "Addressing the need for change".

Mr Leedman is presenting on Day 2 of the conference at 11:30am AEST on 23 September 2021.

In keeping with the theme, Mr Leedman will focus specifically on addressing new needs in patient care. He will also be providing an update on NTI's recent developments and an overview of future plans, including how the Company will address the latest medical needs for neurological disorders and recent clinical developments.

To access further details of the event and to register at no cost, please copy and paste the following link into your internet browser:

**<https://bit.ly/3CbXCg1>**

This announcement has been authorised for release by the Chairman of the Company.

### Further Information

Brian Leedman  
Chairman  
b.leedman@neurotechinternational.com  
+61 (0)41 228 1780

Winton Willesee  
Non-Executive Director  
winton@azc.com.au  
+61 (0)41 066 7844

**Media:**  
Juliana Roadley  
IR Department  
juliana.roadley@irdepartment.com.au  
+61 (0)41 488 9863

### About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>